Alcor Life Extension Foundation

Alcor is not an investment but a fifty-three-year-old institution, and on the terms that matter for a cryonics nonprofit — organizational durability, standby capability, and member trust — it is the field's strongest operator. As a Scottsdale 501(c)(3) it reported roughly 248 patients in cryostasis and over 1,440 members as of April 2025, and its 2025 year-in-review recorded the single best month for new signups in its history in November, evidence that the "don't die" cultural wave and figures like Bryan Johnson are pulling fresh members into a field long dismissed as fringe. The viability moat is operational: Alcor's DART standby-stabilization-transport network is the largest in cryonics, and in 2025 it added a traveling surgeon, a portable washout system, a dedicated headquarters bay, and a reserve team formed from surplus applicants — the difference between a good preservation and ice-damaged tissue is decided in the first minutes after legal death, and Alcor invests where that battle is fought. The prepaid, life-insurance-funded contract model aligns member incentives with the foundation's permanence, and the Patient Care Trust is structured to fund indefinite liquid-nitrogen maintenance independent of operating dues. In a category defined by counterparties that fold, Alcor's mission-risk profile is the most defensible: the oldest name, the largest patient population, the deepest field capability, and rising demand.